Cargando…

A proprietary blend of quail egg for the attenuation of nasal provocation with a standardized allergenic challenge: a randomized, double-blind, placebo-controlled study

Occasional rhinitis symptoms caused by exposure to pollution or allergens is a growing concern. Based first on empirical observation of a lesser occurrence of allergies in quail farmers and then scientific works on ovomucoids properties, we developed a dietary supplement for the relief of such occas...

Descripción completa

Detalles Bibliográficos
Autores principales: Benichou, Annie-Claude, Armanet, Marion, Bussière, Anthony, Chevreau, Nathalie, Cardot, Jean-Michel, Tétard, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4256569/
https://www.ncbi.nlm.nih.gov/pubmed/25493182
http://dx.doi.org/10.1002/fsn3.147
_version_ 1782347604107984896
author Benichou, Annie-Claude
Armanet, Marion
Bussière, Anthony
Chevreau, Nathalie
Cardot, Jean-Michel
Tétard, Jan
author_facet Benichou, Annie-Claude
Armanet, Marion
Bussière, Anthony
Chevreau, Nathalie
Cardot, Jean-Michel
Tétard, Jan
author_sort Benichou, Annie-Claude
collection PubMed
description Occasional rhinitis symptoms caused by exposure to pollution or allergens is a growing concern. Based first on empirical observation of a lesser occurrence of allergies in quail farmers and then scientific works on ovomucoids properties, we developed a dietary supplement for the relief of such occasional rhinitis symptoms. The objective of the study was to determine whether one acute oral dose of the study product attenuates nasal provocation and other allergy-related symptoms after exposure to a standardized allergenic challenge as compared to placebo. Healthy subjects were recruited to participate in a randomized, double-blind, two-arm crossover, placebo-controlled, clinical trial. One acute dose of either the active study product (proprietary blend of quail egg) or placebo was given concomitantly to the standardized allergenic challenge. The primary endpoint was peak nasal inspiratory flow (PNIF) measurement and the secondary endpoints were subjects' perceived feelings of well-being based on Visual Analog Scale (VAS) scores for allergy-related symptoms, as well as immunoglobulin E count. Forty-three healthy subjects were enrolled and evaluable in a per protocol analysis. A gradual increase in PNIF from nadir up to Time 120 reflected the normal, gradual recovery from nasal obstruction induced by allergenic challenge for both the active and the placebo groups. At all postchallenge time points, the active group had higher PNIF values compared to the placebo group, indicating that the active product was associated with fewer symptoms and reduced intensity of these symptoms. The active product resulted also in statistically significant improvements of most of the subjects' perceived feelings of well-being based on VAS scores. No adverse events occurred during the study. In conclusion, the dietary supplement consisting of proprietary blend made of quail eggs provides fast and efficient relief of allergic rhinitis symptoms caused by the most common outdoor and indoor allergens, without adverse events.
format Online
Article
Text
id pubmed-4256569
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BlackWell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-42565692014-12-09 A proprietary blend of quail egg for the attenuation of nasal provocation with a standardized allergenic challenge: a randomized, double-blind, placebo-controlled study Benichou, Annie-Claude Armanet, Marion Bussière, Anthony Chevreau, Nathalie Cardot, Jean-Michel Tétard, Jan Food Sci Nutr Original Research Occasional rhinitis symptoms caused by exposure to pollution or allergens is a growing concern. Based first on empirical observation of a lesser occurrence of allergies in quail farmers and then scientific works on ovomucoids properties, we developed a dietary supplement for the relief of such occasional rhinitis symptoms. The objective of the study was to determine whether one acute oral dose of the study product attenuates nasal provocation and other allergy-related symptoms after exposure to a standardized allergenic challenge as compared to placebo. Healthy subjects were recruited to participate in a randomized, double-blind, two-arm crossover, placebo-controlled, clinical trial. One acute dose of either the active study product (proprietary blend of quail egg) or placebo was given concomitantly to the standardized allergenic challenge. The primary endpoint was peak nasal inspiratory flow (PNIF) measurement and the secondary endpoints were subjects' perceived feelings of well-being based on Visual Analog Scale (VAS) scores for allergy-related symptoms, as well as immunoglobulin E count. Forty-three healthy subjects were enrolled and evaluable in a per protocol analysis. A gradual increase in PNIF from nadir up to Time 120 reflected the normal, gradual recovery from nasal obstruction induced by allergenic challenge for both the active and the placebo groups. At all postchallenge time points, the active group had higher PNIF values compared to the placebo group, indicating that the active product was associated with fewer symptoms and reduced intensity of these symptoms. The active product resulted also in statistically significant improvements of most of the subjects' perceived feelings of well-being based on VAS scores. No adverse events occurred during the study. In conclusion, the dietary supplement consisting of proprietary blend made of quail eggs provides fast and efficient relief of allergic rhinitis symptoms caused by the most common outdoor and indoor allergens, without adverse events. BlackWell Publishing Ltd 2014-11 2014-07-20 /pmc/articles/PMC4256569/ /pubmed/25493182 http://dx.doi.org/10.1002/fsn3.147 Text en © 2014 Stragen Pharma S.A.Food Science & Nutrition published by Wiley Periodicals, Inc. http://creativecommons.org/licenses/by/3.0/ This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research
Benichou, Annie-Claude
Armanet, Marion
Bussière, Anthony
Chevreau, Nathalie
Cardot, Jean-Michel
Tétard, Jan
A proprietary blend of quail egg for the attenuation of nasal provocation with a standardized allergenic challenge: a randomized, double-blind, placebo-controlled study
title A proprietary blend of quail egg for the attenuation of nasal provocation with a standardized allergenic challenge: a randomized, double-blind, placebo-controlled study
title_full A proprietary blend of quail egg for the attenuation of nasal provocation with a standardized allergenic challenge: a randomized, double-blind, placebo-controlled study
title_fullStr A proprietary blend of quail egg for the attenuation of nasal provocation with a standardized allergenic challenge: a randomized, double-blind, placebo-controlled study
title_full_unstemmed A proprietary blend of quail egg for the attenuation of nasal provocation with a standardized allergenic challenge: a randomized, double-blind, placebo-controlled study
title_short A proprietary blend of quail egg for the attenuation of nasal provocation with a standardized allergenic challenge: a randomized, double-blind, placebo-controlled study
title_sort proprietary blend of quail egg for the attenuation of nasal provocation with a standardized allergenic challenge: a randomized, double-blind, placebo-controlled study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4256569/
https://www.ncbi.nlm.nih.gov/pubmed/25493182
http://dx.doi.org/10.1002/fsn3.147
work_keys_str_mv AT benichouannieclaude aproprietaryblendofquaileggfortheattenuationofnasalprovocationwithastandardizedallergenicchallengearandomizeddoubleblindplacebocontrolledstudy
AT armanetmarion aproprietaryblendofquaileggfortheattenuationofnasalprovocationwithastandardizedallergenicchallengearandomizeddoubleblindplacebocontrolledstudy
AT bussiereanthony aproprietaryblendofquaileggfortheattenuationofnasalprovocationwithastandardizedallergenicchallengearandomizeddoubleblindplacebocontrolledstudy
AT chevreaunathalie aproprietaryblendofquaileggfortheattenuationofnasalprovocationwithastandardizedallergenicchallengearandomizeddoubleblindplacebocontrolledstudy
AT cardotjeanmichel aproprietaryblendofquaileggfortheattenuationofnasalprovocationwithastandardizedallergenicchallengearandomizeddoubleblindplacebocontrolledstudy
AT tetardjan aproprietaryblendofquaileggfortheattenuationofnasalprovocationwithastandardizedallergenicchallengearandomizeddoubleblindplacebocontrolledstudy
AT benichouannieclaude proprietaryblendofquaileggfortheattenuationofnasalprovocationwithastandardizedallergenicchallengearandomizeddoubleblindplacebocontrolledstudy
AT armanetmarion proprietaryblendofquaileggfortheattenuationofnasalprovocationwithastandardizedallergenicchallengearandomizeddoubleblindplacebocontrolledstudy
AT bussiereanthony proprietaryblendofquaileggfortheattenuationofnasalprovocationwithastandardizedallergenicchallengearandomizeddoubleblindplacebocontrolledstudy
AT chevreaunathalie proprietaryblendofquaileggfortheattenuationofnasalprovocationwithastandardizedallergenicchallengearandomizeddoubleblindplacebocontrolledstudy
AT cardotjeanmichel proprietaryblendofquaileggfortheattenuationofnasalprovocationwithastandardizedallergenicchallengearandomizeddoubleblindplacebocontrolledstudy
AT tetardjan proprietaryblendofquaileggfortheattenuationofnasalprovocationwithastandardizedallergenicchallengearandomizeddoubleblindplacebocontrolledstudy